Anti-IL-6 Versus Anti-IL-6R Blocking Antibodies to Treat Acute Ebola Infection in BALB/c Mice: Potential Implications for Treating Cytokine Release Syndrome

MLA

Reid Rubsamen, et al. “Anti-IL-6 Versus Anti-IL-6R Blocking Antibodies to Treat Acute Ebola Infection in BALB/c Mice: Potential Implications for Treating Cytokine Release Syndrome.” Frontiers in Pharmacology, vol. 11, Sept. 2020. EBSCOhost, https://doi.org/10.3389/fphar.2020.574703.

APA

Reid Rubsamen, Scott Burkholz, Christopher Massey, Trevor Brasel, Tom Hodge, Lu Wang, Charles Herst, Richard Carback, & Paul Harris. (2020). Anti-IL-6 Versus Anti-IL-6R Blocking Antibodies to Treat Acute Ebola Infection in BALB/c Mice: Potential Implications for Treating Cytokine Release Syndrome. Frontiers in Pharmacology, 11. https://doi.org/10.3389/fphar.2020.574703

Chicago

Reid Rubsamen, Scott Burkholz, Christopher Massey, Trevor Brasel, Tom Hodge, Lu Wang, Charles Herst, Richard Carback, and Paul Harris. 2020. “Anti-IL-6 Versus Anti-IL-6R Blocking Antibodies to Treat Acute Ebola Infection in BALB/c Mice: Potential Implications for Treating Cytokine Release Syndrome.” Frontiers in Pharmacology 11 (September). doi:10.3389/fphar.2020.574703.